Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate

Summary

Xenon Pharmaceuticals' epilepsy candidate azetukalner continues to be evaluated for its potential in the epilepsy treatment space. The article provides commentary on the drug's prospects without announcing specific clinical data or regulatory developments.